<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33538">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01969019</url>
  </required_header>
  <id_info>
    <org_study_id>CCEMD015</org_study_id>
    <nct_id>NCT01969019</nct_id>
  </id_info>
  <brief_title>A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy</brief_title>
  <official_title>A Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to compare the efficacy and safety of 4.5g iv MP administered in 12
      weeks and 4 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of CAS, adverse effects and retreat</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Graves' Ophthalmopathy</condition>
  <arm_group>
    <arm_group_label>methylprednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous MP: 0.5g weekly for six weeks followed by 0.25g weekly for six weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>methylprednisolone plus prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous MP 0.5g daily for three days per week, twice, followed by 0.25g daily for three days per week, twice, and followed by tapering oral prednisone (starting with 60mg/d, then10 mg less/week than each previous week for the next 3 weeks, then20mg/week at the 5th week followed with 5mg less/week than each previous week for the next 3 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone, prednisone</intervention_name>
    <arm_group_label>methylprednisolone</arm_group_label>
    <arm_group_label>methylprednisolone plus prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients should meet the criteria of either a or b and together with c, d and e to
             include into the study.

             a. Lid retraction with any one of the following: i) Thyroid dysfunction ii) Proptosis
             iii) Optic nerve involvement iv) Extraocular muscle involvement b. Thyroid
             dysfunction with any one of the following: i) Proptosis ii) Optic nerve involvement
             iii) Extraocular muscle involvement c. Exclude cases with such ophthalmological signs
             caused by other diseases. d. Moderate to severe patients defined by EUGOGO. e.
             Clinical activity score (CAS)≥3/7 f. Normal function of heart, liver and kidney.

        Exclusion Criteria:

          -  Orbital decompression surgery needed immediately

          -  History of chronic recurrent or active infection

          -  History of peptic ulcer

          -  Patients with a history of chronic liver disease or liver disorders； ALT or AST above
             2.5 times upper limit of normal

          -  History of HIV, hepatitis C or hepatitis B Positive

          -  Cardiovascular or cerebrovascular disease clinically significant

          -  Uncontrolled diabetes mellitus

          -  Use of corticosteroids during 12 weeks before to inclusion period

          -  Pregnant patient or patient who is planning to become pregnant during the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ning Guang, Professor</last_name>
    <phone>(8621)64370045</phone>
    <phone_ext>665344</phone_ext>
    <email>guangning@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Institute of Endocrine and Metabolic Diseases Department of Endocrine and Metabolic Diseases, Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Zhu, Attending</last_name>
      <phone>(8621)64370045</phone>
      <phone_ext>602105</phone_ext>
      <email>juvey1515@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 21, 2013</lastchanged_date>
  <firstreceived_date>October 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Wei Zhu</investigator_full_name>
    <investigator_title>Attending</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
